Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 18/20 | 0.60 |
| ▸ | GABRD | O14764 | 1/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16600152 | 1.00 | GPR183 (0.60) | GPR183GABRDGABRA1GABRB1GABRA5 | |
| SCHEMBL16600265 | 0.87 | GPR183 (0.76) | GPR183KCNH2ENPP2ATXN2 | |
| SCHEMBL16600267 | 0.87 | GPR183 (0.76) | GPR183KCNH2ENPP2ATXN2 | |
| SCHEMBL16600234 | 0.86 | GPR183 (0.61) | GPR183KCNH2 | |
| SCHEMBL16600236 | 0.86 | GPR183 (0.61) | GPR183KCNH2 | |
| SCHEMBL17853001 | 0.86 | GPR183 (0.56) | GPR183KCNH2ENPP2ATXN2 | |
| SCHEMBL16600273 | 0.82 | ENPP2 (0.62) | GPR183KCNH2ENPP2ATXN2 | |
| SCHEMBL16600276 | 0.82 | ENPP2 (0.62) | GPR183KCNH2ENPP2ATXN2 | |
| SCHEMBL16600021 | 0.82 | GPR183 (0.69) | GPR183KCNH2 | |
| SCHEMBL16599834 | 0.82 | GPR183 (0.69) | GPR183KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196369-B2 | Spirocyclic EBI2 modulators | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-02-05 | — | — | US | disclosed |
| US-20160176875-A1 | SPIROCYCLIC EBI2 MODULATORS | Sanford Burnham Prebys Medical Discovery Institute | 2016-06-23 | — | — | US | disclosed |
| WO-2015048567-A1 | SPIROCYCLIC EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176875-A1 | SPIROCYCLIC EBI2 MODULATORS | HAVCR2, BIRC2, ESR2 | GPR183 17/4885GABRD 1523/4885GABRA1 623/4885 |
| US-10196369-B2 | Spirocyclic EBI2 modulators | HAVCR2, BIRC2, ESR2 | GPR183 17/4885GABRD 1523/4885GABRA1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.